Almirall, S.A.
BME:ALM Voorraadrapport
Marktkapitalisatie: €1.8b
Almirall Inkomsten in het verleden We zijn nog bezig met het verwerken van het laatste winstrapport van dit bedrijf
Verleden criteriumcontroles 0/6 De winst van Almirall is gedaald met een gemiddeld jaarlijks percentage van -62.1%, terwijl de winst van de Pharmaceuticals -industrie jaarlijks groeide met 13.1%. De inkomsten zijn groeide met een gemiddeld percentage van 1% per jaar.
Belangrijke informatie
-61.0%
Groei van de winst per aandeel
Pharmaceuticals Groei van de industrie 5.0% Inkomstengroei 1.0% Rendement op eigen vermogen -2.4% Nettomarge -3.8% Laatste winstupdate 30 Jun 2024
Recente prestatie-updates uit het verleden
Second quarter 2024 earnings released Jul 24
Full year 2023 earnings: EPS misses analyst expectations Feb 22
Third quarter 2023 earnings released: EPS: €0.008 (vs €0.089 loss in 3Q 2022) Nov 13 Almirall, S.A. to Report Fiscal Year 2023 Results on Feb 19, 2024
Second quarter 2023 earnings released Jul 24
First quarter 2023 earnings released May 10
Toon alle updates
Almirall, S.A. Reiterates Earnings Guidance for Full Year 2024 Nov 11
Almirall (BME:ALM) Has A Somewhat Strained Balance Sheet Nov 06
Investors Continue Waiting On Sidelines For Almirall, S.A. (BME:ALM) Sep 07
Second quarter 2024 earnings released Jul 24
Almirall, S.A. Reiterates Financial Guidance for Full Year 2024 Jul 22
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 90% Above Its Share Price Jul 12
Insufficient new directors Jul 01
Almirall’s Ilumetri® (tildrakizumab) Restores and Maintains Wellbeing of Patients With Moderate-to-severe Plaque Psoriasis to the Levels of the General Population for up to 1 Year Jun 29
Dividend of €0.15 announced May 15 Almirall, S.A. Provides Earnings Guidance for Full Year 2024
Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues Apr 24
Almirall, S.A., Annual General Meeting, May 10, 2024 Apr 09
These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well Mar 20
Full year 2023 earnings: EPS misses analyst expectations Feb 22
Almirall, S.A. Provides Earnings Guidance for the Year 2024 Feb 20
Consensus EPS estimates increase by 15% Jan 30
Almirall S.A. Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases Dec 21
Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly Dec 15
Consensus EPS estimates increase by 29% Nov 19
Almirall, S.A. Receives European Commission Approval of EBGLYSS(R) (lebrikizumab) for Moderate to-Severe Atopic Dermatitis Nov 18
Third quarter 2023 earnings released: EPS: €0.008 (vs €0.089 loss in 3Q 2022) Nov 13 Almirall, S.A. to Report Fiscal Year 2023 Results on Feb 19, 2024
Almirall's Ilumetri (Tildrakizumab) Significantly Improves Wellbeing for Patients and Their Relatives in Moderate-To-Severe Plaque Psoriasis Oct 12
Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation? Oct 03
Now 21% undervalued Sep 21
We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt Aug 24
New minor risk - Shareholder dilution Jul 26
Almirall, S.A. Reiterates Earnings Guidance for the Year 2023 Jul 25
Second quarter 2023 earnings released Jul 24
Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 31% Undervaluation? Jul 05
Almirall Launches Nina, the First Series to Highlight the Major Impact of Psoriasis on Patient’s Wellbeing Jun 20 Almirall, S.A. has completed a Follow-on Equity Offering in the amount of €199.999993 million. Jun 14
New minor risk - Dividend sustainability Jun 13
Is Almirall (BME:ALM) A Risky Investment? May 16
First quarter 2023 earnings released May 10
Consensus EPS estimates fall by 26% May 09
Almirall, S.A. Reiterates Earnings Guidance for the Year 2023 May 08
Estimating The Fair Value Of Almirall, S.A. (BME:ALM) Mar 29
Full year 2022 earnings released: EPS: €0.02 (vs €0.23 loss in FY 2021) Feb 21 Almirall, S.A., Annual General Meeting, May 05, 2023
Now 20% undervalued after recent price drop Feb 13
Price target decreased by 7.2% to €11.93 Feb 01
We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt Jan 04
Now 20% undervalued Dec 09
An Intrinsic Calculation For Almirall, S.A. (BME:ALM) Suggests It's 29% Undervalued Dec 01 Almirall, S.A. to Report Nine Months, 2023 Results on Nov 16, 2023
Almirall, S.A. Maintains Earnings Guidance for the Full Year of 2022 Nov 10
Almirall, S.A. Announces EMA Acceptance for Filing of Marketing Authorization Application (MAA) for Lebrikizumab in Atopic Dermatitis Oct 28
Almirall, S.A. Announces the 31st EADV Congress the Results from TRIBUTE, an Interventional Phase IV Clinical Study Sep 15
Almirall, S.A. Announces New Detailed Results from Phase 3 Monotherapy Studies in Atopic Dermatitis Sep 09
Second quarter 2022 earnings: EPS misses analyst expectations Jul 26
Almirall (BME:ALM) Seems To Use Debt Quite Sensibly Jul 14
Almirall, S.A.(BME:ALM) dropped from Madrid Ibex 35 Index Jun 22
Happify Health and Almirall, S.A. Go Live with Digital Solution to Support Psoriasis Patients Jun 14
Almirall, S.A. Announces Topline Results from One-Year Analyses of the Efficacy and Safety of Lebrikizumab Jun 07
Almirall, S.A. Announces Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis Apr 12
Now 21% undervalued Mar 31
Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly Mar 23
Now 22% undervalued Mar 03
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 82% Above Its Share Price Feb 24
Full year 2021 earnings: EPS and revenues miss analyst expectations Feb 22 Almirall, S.A. Announces Executive Changes
Almirall launches innovative Wynzora® CAL/BDP cream in Europe for the treatment of mild to moderate plaque psoriasis in adults including scalp Feb 19
Almirall Announces Results for Atopic Dermatitis in Third Phase 3 Study Dec 21
Price target decreased to €14.66 Nov 16
Is Almirall (BME:ALM) Using Too Much Debt? Nov 01
Almirall, S.A. Launches Klisyri (Tirbanibulin) for the Treatment of Actinic Keratosis in Europe Sep 29
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 77% Above Its Share Price Aug 02
Second quarter 2021 earnings released: €0.40 loss per share (vs €0.036 loss in 2Q 2020) Jul 27
Almirall, S.A. Receives European Commission Approval of Klisyri® (Tirbanibulin) Jul 20
Almirall and MC2 Therapeutics Announce Completion of Decentralized Procedure in Europe for the Topical Treatment of Mild to Moderate Psoriasis Vulgaris in Adults Jul 07
Is Almirall (BME:ALM) Using Too Much Debt? Jul 06
Almirall Receives Positive CHMP Opinion for Klisyri®? (Tirbanibulin), an Innovative Topical Treatment for Actinic Keratosis May 22
First quarter 2021 earnings released: EPS €0.17 (vs €0.28 in 1Q 2020) May 14
Consensus forecasts updated May 11
Here's Why Almirall (BME:ALM) Has A Meaningful Debt Burden Mar 23
New 90-day high: €12.19 Mar 15
How Does Almirall, S.A. (BME:ALM) Fare As A Dividend Stock? Mar 05
Revenue behind estimates Feb 25
Full year 2020 earnings released: EPS €0.42 (vs €0.61 in FY 2019) Feb 25
Analysts lower EPS estimates to €0.46 Feb 23
Almirall U.S. Launches Klisyri® (tirbanibulin), a New, Innovative Topical Treatment for Actinic Keratosis Feb 19
Almirall and MC2 Therapeutics Enters a License, Collaboration and Commercialization Agreement for European Rights to Wynzora® Cream for treatment of Plaque Psoriasis Feb 18
Almirall, S.A. (BME:ALM) Shares Could Be 41% Below Their Intrinsic Value Estimate Feb 15
Analysts lower EPS estimates to €0.43 Feb 12
Hoe Almirall geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis BME:ALM Opbrengsten, kosten en inkomsten (EUR Millions ) Datum Inkomsten Inkomsten G+A Uitgaven R&D-uitgaven 30 Jun 24 932 -35 220 0 31 Mar 24 915 -39 214 3 31 Dec 23 899 -38 209 0 30 Sep 23 907 7 209 7 30 Jun 23 898 -11 201 0 31 Mar 23 882 -8 205 3 31 Dec 22 879 4 202 0 30 Sep 22 864 9 207 24 30 Jun 22 856 29 197 0 31 Mar 22 843 -50 190 8 31 Dec 21 837 -41 188 0 30 Sep 21 814 -22 201 -10 30 Jun 21 809 -11 185 0 31 Mar 21 790 55 188 -8 31 Dec 20 814 74 177 0 30 Sep 20 849 63 167 -8 30 Jun 20 872 86 188 0 31 Mar 20 926 121 188 0 31 Dec 19 911 106 189 0 30 Sep 19 858 85 227 9 30 Jun 19 884 88 182 0 31 Mar 19 789 80 209 3 31 Dec 18 811 78 183 0 30 Sep 18 714 -111 176 -10 30 Jun 18 730 -179 196 0 31 Mar 18 687 -293 195 -6 31 Dec 17 677 -304 207 0 30 Sep 17 735 -128 215 5 30 Jun 17 755 -78 214 0 31 Mar 17 821 73 216 5 31 Dec 16 822 75 213 0 30 Sep 16 778 162 230 10 30 Jun 16 743 154 210 0 31 Mar 16 721 111 204 2 31 Dec 15 738 132 201 0 30 Sep 15 783 479 190 -28 30 Jun 15 802 488 244 0 31 Mar 15 842 481 250 -11 31 Dec 14 828 448 274 0 30 Sep 14 868 -13 262 -11 30 Jun 14 849 -32 256 0 31 Mar 14 845 -33 261 0 31 Dec 13 825 -34 250 0
Kwaliteitswinsten: ALM is momenteel verliesgevend.
Groeiende winstmarge: ALM is momenteel verliesgevend.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: ALM is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 62.1% per jaar.
Versnelling van de groei: Het is niet mogelijk om de winstgroei van ALM over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.
Winst versus industrie: ALM is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Pharmaceuticals industrie ( 8.8% ).
Rendement op eigen vermogen
Hoge ROE: ALM heeft een negatief Return on Equity ( -2.36% ), omdat het momenteel verliesgevend is.
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
